Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation

American Journal of Translational Research

Volumn 3, Issue 5, 2011, Pages 404-421

  Rutella, Sergio ^a,b   Locatelli, Franco ^a,c  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Adenovirus; Adoptive cell therapy; Aspergillus; Candida; Cytomegalovirus; Epstein Barr virus; Immune reconstitution; Stem cell transplantation

Indexed keywords

CIDOFOVIR; EPRATUZUMAB; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; INTERLEUKIN 2; RIBAVIRIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ADENOVIRUS INFECTION; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; GOOD MANUFACTURING PRACTICE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HAPLOIDY; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; IN VITRO STUDY; INFECTION; LOW DRUG DOSE; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; VIRUS INFECTION;

ADENOVIRIDAE; ASPERGILLUS; CANDIDA; CYTOMEGALOVIRUS; FUNGI; HARNESS; HUMAN HERPESVIRUS 4;

EID: 80054728483     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C, Remberger M, Michel G, Arcese W, Dallorso S, Tiedemann K, Busca A, Chan KW, Kato S, Ortega J, Vowels M, Zander A, Souillet G, Oakill A, Woolfrey A, Pay AL, Green A, Garnier F, Ionescu I, Wernet P, Sirchia G, Rubinstein P, Chevret S and Gluckman E. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97: 2962-2971.
2. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F, Ruggeri L, Barbabietola G, Aristei C, Latini P, Reisner Y and Martelli MF. Treatment of high-risk acute leukemia with Tcell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186-1193.
3. Rocha V and Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant 2008; 41: 207-214.
4. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, Balduzzi A, Owoc-Lempach J, Fagioli F, Or R, Peters C, Aversa F, Polge E, Dini G and Rocha V. Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010; 115: 3437-3446.
5. Lang P, Greil J, Bader P, Handgretinger R, Klingebiel T, Schumm M, Schlegel PG, Feuchtinger T, Pfeiffer M, Scheel-Walter H, Fuhrer M, Martin D and Niethammer D. Long-term outcome after haploidentical stem cell transplantation in children. Blood Cells Mol Dis 2004; 33: 281-287.
6. + cells: analysis of predictive factors and comparison with unselected progenitor transplants. Br J Haematol 2000; 108: 105-115.
7. Seggewiss R and Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010; 115: 3861-3868.
8. Testa U, Martucci R, Rutella S, Scambia G, Sica S, Benedetti Panici P, Pierelli L, Menichella G, Leone G and Mancuso S. Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery. Blood 1994; 84: 3532-3539.
9. + progenitor cells from HLAmismatched parental donors in children. Bone Marrow Transplant 2001; 27: 777-783.
10. Handgretinger R, Lang P, Schumm M, Pfeiffer M, Gottschling S, Demirdelen B, Bader P, Kuci S, Klingebiel T and Niethammer D. Immunological aspects of haploidentical stem cell transplantation in children. Ann N Y Acad Sci 2001; 938: 340-357; discussion 357-348.
11. Ball LM, Lankester AC, Bredius RG, Fibbe WE, van Tol MJ and Egeler RM. Graft dysfunction and delayed immune reconstitution following haploidentical peripheral blood hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 35 Suppl 1: S35-38.
12. Fujita Y, Rooney CM and Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant 2008; 41: 193-198.
13. Leen AM, Tripic T and Rooney CM. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation. Expert Opin Biol Ther 2010; 10: 337-351.
14. Safdar A, Hanna HA, Boktour M, Kontoyiannis DP, Hachem R, Lichtiger B, Freireich EJ and Raad II. Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infections. Cancer 2004; 101: 2859-2865.
15. Roilides E and Walsh T. Recombinant cytokines in augmentation and immunomodulation of host defenses against Candida spp. Med Mycol 2004; 42: 1-13.
16. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP and Small TN. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-1191.
17. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J and Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997; 157: 195-216.
18. Leen AM and Heslop HE. Cytotoxic T lymphocytes as immune-therapy in haematological practice. Br J Haematol 2008; 143: 169-179.
19. Mielke S, Nunes R, Rezvani K, Fellowes VS, Venne A, Solomon SR, Fan Y, Gostick E, Price DA, Scotto C, Read EJ and Barrett AJ. A clinicalscale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402.-based photodepletion technique. Blood 2008; 111: 4392-4402.
20. Perruccio K, Topini F, Tosti A, Carotti A, Aloisi T, Aversa F, Martelli MF and Velardi A. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. Blood Cells Mol Dis 2008; 40: 76-83.
21. Roy DC, Lachance S, Kiss T, Cohen S, Busque L, Fish D, Sauvageau G, Egeler M and Roy J. Haploidentical stem cell transplantation: High doses of alloreactive-T cell depleted donor lymphocytes administered post-transplant decrease infections and improve survival without causing severe GVHD. Blood 2009; 114: A512.
22. Mielke S, Shenoy A, Rezvani K, Yong ASM, McIver ZA, Fellowes VS, Savani BN, Kurlander R, Khuu H, Boss C and Barrett AJ. Allografts selectively photodepleted of GVHD causing T cells and followed by low-level immunosuppression: A novel method to improve disease control after HLA-matched sibling transplantations. Blood 2009; 114: 515A.
23. McIver ZA, Mielke S, Shenoy A, Fellows V, Stroncek D, Leitman S, Childs R, Battiwalla M, Koklanaris EK, Haggerty J, Savani BN, Rezvani K and Barrett AJ. Selectively T cell depleted allografts from HLA-matched sibling donors followed by low-dose post-transplant immunosuppression to limit disease relapse in patients with hematological malignancies. Blood 2010; 116: 4705A.
24. Amrolia PJ, Muccioli-Casadei G, Huls H, Adams S, Durett A, Gee A, Yvon E, Weiss H, Cobbold M, Gaspar HB, Rooney C, Kuehnle I, Ghetie V, Schindler J, Krance R, Heslop HE, Veys P, Vitetta E and Brenner MK. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 2006; 108: 1797-1808.
25. Andre-Schmutz I, Le Deist F, Hacein-Bey-Abina S, Vitetta E, Schindler J, Chedeville G, Vilmer E, Fischer A and Cavazzana-Calvo M. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a phase 1/2 study. Lancet 2002; 360: 130-137.
26. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, Hensel N, Schindler J, Ghetie V, Leitman SF, Mai T, Carter CS, Kurlander R, Read EJ, Vitetta ES and Barrett AJ. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graftversus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005; 106: 1123-1129.
27. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED and Riddell SR. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
28. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L, Kleihauer A, Frank F, Jahn G and Hebart H. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916-3922.
29. Peggs KS, Verfuerth S, Pizzey A, Khan N, Guiver M, Moss PA and Mackinnon S. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virusspecific T-cell lines. Lancet 2003; 362: 1375-1377.
30. Micklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V, Sartor MM, Bradstock KF and Gottlieb DJ. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 genemodified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood 2008; 112: 3974-3981.
31. + T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004; 103: 3565-3572.
32. Schub A, Schuster IG, Hammerschmidt W and Moosmann A. CMV-specific TCR-transgenic T cells for immunotherapy. J Immunol 2009; 183: 6819-6830.
33. Jones K, Nourse JP, Morrison L, Nguyen-Van D, Moss DJ, Burrows SR and Gandhi MK. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood 2010; 116: 2245-2252.
34. Meijer E, Cornelissen JJ. Epstein-Barr virusassociated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 2008; 15: 576-585.
35. Long HM, Taylor GS and Rickinson AB. Immune defence against EBV and EBV-associated disease. Curr Opin Immunol 2011; 23: 258-264.
36. Handgretinger R, Chen X, Pfeiffer M, Schumm M, Mueller I, Feuchtinger T, Hale G and Lang P. Cellular immune reconstitution after haploidentical transplantation in children. Biol Blood Marrow Transplant 2008; 14: 59-65.
37. Chen X, Hale GA, Barfield R, Benaim E, Leung WH, Knowles J, Horwitz EM, Woodard P, Kasow K, Yusuf U, Behm FG, Hayden RT, Shurtleff SA, Turner V, Srivastava DK and Handgretinger R. Rapid immune reconstitution after a reducedintensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol 2006; 135: 524-532.
38. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK and Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
39. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK and Rooney CM. Longterm restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-555.
40. Comoli P, Basso S, Labirio M, Baldanti F, Maccario R and Locatelli F. T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis 2008; 40: 68-70.
41. De Angelis B, Dotti G, Quintarelli C, Huye LE, Zhang L, Zhang M, Pane F, Heslop HE, Brenner MK, Rooney CM and Savoldo B. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 2009; 114: 4784-4791.
42. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, Heslop HE and Rooney CM. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001; 97: 835-843.
43. Lindemans CA, Leen AM and Boelens JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 2010; 116: 5476-5485.
44. Myers GD, Bollard CM, Wu MF, Weiss H, Rooney CM, Heslop HE and Leen AM. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39: 677-686.
45. Hromas R, Cornetta K, Srour E, Blanke C and Broun ER. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after Tcell-depleted bone marrow transplantation. Blood 1994; 84: 1689-1690.
46. Bordigoni P, Carret AS, Venard V, Witz F and Le Faou A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32: 1290-1297.
47. + T cells according to IFN-g secretion for adjuvant immunotherapy. Exp Hematol 2004; 32: 282-289.
48. Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, Heslop HE, Rooney CM and Bollard CM. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol 2008; 82: 546-554.
49. Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K, Handgretinger R, Peters C, Schuster FR, Beck R, Schumm M, Lotfi R, Jahn G and Lang P. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64-76.
50. Feuchtinger T, Richard C, Joachim S, Scheible MH, Schumm M, Hamprecht K, Martin D, Jahn G, Handgretinger R and Lang P. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 2008; 31: 199-206.
51. Comoli P, Schilham MW, Basso S, van Vreeswijk T, Bernardo ME, Maccario R, van Tol MJ, Locatelli F and Veltrop-Duits LA. T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLAhaploidentical donors. J Immunother 2008; 31: 529-536.
52. Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM and Bollard CM. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood 2009; 114: 4283-4292.
53. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, Gee AP, Brenner MK, Heslop HE, Rooney CM and Bollard CM. Monoculturederived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-1166.
54. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2: 389-400.
55. Sakaguchi S, Sakaguchi N, Asano M, Itoh M and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
56. + regulatory T cells in cancer and autoimmunity. Curr Med Chem 2007; 14: 649-666.
57. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-811.
58. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Iacucci Ostini R, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F and Martelli MF. Tregs prevent GvHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011; doi:10.1182/ blood-2010-10-311894: Feb 3.
59. Romani L. Immunity to fungal infections. Nat Rev Immunol 2011; 11: 275-288.
60. Brown GD. Innate antifungal immunity: the key role of phagocytes. Annu Rev Immunol 2011; 29: 1-21.
61. Zelante T, De Luca A, D'Angelo C, Moretti S and Romani L. IL-17/Th17 in anti-fungal immunity: what's new? Eur J Immunol 2009; 39: 645-648.
62. Tramsen L, Schmidt S, Roeger F, Koehl U and Lehrnbecher T. Challenges and prospects of adoptive immunotherapy in prevention and treatment of opportunistic mycoses in hematologic transplant recipients. Curr Infect Dis Rep 2010; 12: 444-449.
63. Beck O, Koehl U, Tramsen L, Mousset S, Latge JP, Muller K, Schwabe D, Bader P, Klingebiel T and Lehrnbecher T. Enumeration of functionally active anti-Aspergillus T-cells in human peripheral blood. J Immunol Methods 2008; 335: 41-45.
64. Beck O, Topp MS, Koehl U, Roilides E, Simitsopoulou M, Hanisch M, Sarfati J, Latge JP, Klingebiel T, Einsele H and Lehrnbecher T. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood 2006; 107: 2562-2569.
65. Tramsen L, Beck O, Schuster FR, Hunfeld KP, Latge JP, Sarfati J, Roger F, Klingebiel T, Koehl U and Lehrnbecher T. Generation and characterization of anti-Candida T cells as potential immunotherapy in patients with Candida infection after allogeneic hematopoietic stem-cell transplant. J Infect Dis 2007; 196: 485-492.
66. Tramsen L, Koehl U, Tonn T, Latge JP, Schuster FR, Borkhardt A, Uharek L, Quaritsch R, Beck O, Seifried E, Klingebiel T and Lehrnbecher T. Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy. Bone Marrow Transplant 2009; 43: 13-19.
67. Rutella S, Pierelli L, Piccirillo N, Sica S, Serafini R, Chiusolo P, Paladini U, Leone F, Zini G, D'Onofrio G and Leone G. Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. Cytotherapy 2003; 5: 19-30.
68. Bonanno G, Procoli A, Mariotti A, Corallo M, Perillo A, Danese S, De Cristofaro R, Scambia G and Rutella S. Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies. J Transl Med 2010; 8: 114.
69. Rutella S, Pierelli L, Bonanno G, Sica S, Ameglio F, Capoluongo E, Mariotti A, Scambia G, d'Onofrio G and Leone G. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood 2002; 100: 2562-2571.
70. Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S, Aversa F, Tabilio A, Romani L, Martelli MF and Velardi A. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotypemismatched hematopoietic transplants. Blood 2001; 97: 2514-2521.
71. Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A, Capanni M, Urbani E, Mancusi A, Aversa F, Martelli MF, Romani L and Velardi A. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397-4406.
72. Perillo A, Pierelli L, Battaglia A, Salerno MG, Rutella S, Cortesi E, Fattorossi A, De Rosa L, Ferrau F, Lalle M, Leone G, Mancuso S and Scambia G. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer. Bone Marrow Transplant 2002; 30: 571-578.
73. Rutella S, Pierelli L, Bonanno G, Mariotti A, Sica S, Sora F, Chiusolo P, Scambia G, Rumi C and Leone G. Immune reconstitution after autologous peripheral blood progenitor cell transplantation: effect of interleukin-15 on T-cell survival and effector functions. Exp Hematol 2001; 29: 1503-1516.
74. Quintarelli C, Savoldo B and Dotti G. Gene therapy to improve function of T cells for adoptive immunotherapy. Methods Mol Biol 2010; 651: 119-130.
75. Kohn DB, Dotti G, Brentjens R, Savoldo B, Jensen M, Cooper LJ, June CH, Rosenberg S, Sadelain M and Heslop HE. CARs on track in the clinic. Mol Ther 2011; 19: 432-438.
76. Cobbold M, Khan N, Pourgheysari B, Tauro S, McDonald D, Osman H, Assenmacher M, Billingham L, Steward C, Crawley C, Olavarria E, Goldman J, Chakraverty R, Mahendra P, Craddock C and Moss PA. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005; 202: 379-386.
77. + T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011; 51: 591-599.
78. Khanna N, Stuehler C, Conrad B, Lurati S, Krappmann S, Einsele H, Berges C and Topp MS. Generation of a multiple pathogen-specfic T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 2011.
79. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, MacGilchrist A, Gandhi MK, Swerdlow AJ and Crawford DH. Allogeneic cytotoxic T-cell therapy for EBVpositive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123-1131.
80. Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A, Dombagoda D, Britton KM, Swerdlow AJ and Crawford DH. Treatment of Epstein-Barrvirus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360: 436-442.
81. Li Pira G, Kapp M, Manca F and Einsele H. Pathogen specific T-lymphocytes for the reconstitution of the immunocompromised host. Curr Opin Immunol 2009; 21: 549-556.
82. + T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children. Am J Transplant 2006; 6: 2169-2176.
83. Park KD, Marti L, Kurtzberg J and Szabolcs P. In vitro priming and expansion of cytomegalovirusspecific Th1 and Tc1 T cells from naive cord blood lymphocytes. Blood 2006; 108: 1770-1773.